News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hemispherx Biopharma (HEB) Announces New Publication Enlarges The Understanding Of Ampligen® Safety Profile Across Diverse Animal Species And Focuses On The Unique TLR-3 Receptor/Ampligen(R) Interaction



4/8/2014 7:31:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and Toxicological Species Responses to TLR-3 Activation" in the current issue of the American Journal of Pathology Vol. 184 (pages 1062-1072), 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES